Keyphrases
Tumor-infiltrating Lymphocytes
100%
Adoptive Cell Therapy
55%
Checkpoint Inhibitors
35%
Melanoma
33%
T Cells
32%
Inhibitor Resistant
21%
CD8+ Tumor-infiltrating Lymphocytes
18%
Metastatic Melanoma
15%
Tumor Regression
14%
Ovarian Cancer
13%
Tumor
13%
Tumor-specific
12%
Tumor Cells
12%
Sarcoma
12%
Tumor Subtype
12%
IFN Signaling
12%
CD8+ T Cells
12%
CD4+
12%
Autologous Tumor Antigens
11%
Cancer Types
11%
Metastatic Ovarian Cancer
10%
LTX-315
10%
Transcriptomic Signature
10%
Solid Cancer
10%
CD137
10%
Combined Detection
10%
Bystander
10%
Tumor-specific T Cells
10%
Anti-PD-1 Immunotherapy
10%
Metastatic Soft Tissue Sarcoma
10%
Anti-programmed Death 1
10%
Human Tumors
10%
Acquired Resistance
10%
Clinical Efficacy
10%
Checkpoint Inhibition
10%
Non-melanoma Skin Cancer
10%
BRAF Inhibitor (BRAFi)
10%
Rapid Identification
10%
4-1BB
10%
MHC Class I Antigen Presentation
10%
Immune Escape
8%
CD8+
7%
β2-microglobulin (β2-MG)
7%
Janus Kinase 1 (JAK1)
7%
Partial Response
7%
Programmed Death-ligand 1 (PD-L1)
7%
Interleukin-2
6%
Tumor Microenvironment
6%
Vemurafenib
6%
Objective Response
6%
Medicine and Dentistry
Tumor Infiltrating Lymphocyte
70%
T Cell
45%
Cell Therapy
44%
Neoplasm
29%
Nodular Melanoma
25%
Ovarian Cancer
21%
In Vitro
19%
CD8 Antigen
17%
Immunotherapy
16%
Specific Tumor
14%
Tumor Regression
13%
Sarcoma
12%
Antigen Presentation
10%
Soft Tissue Sarcoma
10%
Cancer Types
10%
Transcriptomics
10%
Tumor Cell
10%
Immune Response
9%
Disease
8%
Infusion
7%
Beta 2 Microglobulin
7%
Janus Kinase 1
7%
Interleukin 2
5%
Immunology and Microbiology
Tumor-Infiltrating Lymphocytes
50%
T Cell
42%
Tumor Cell
15%
Immunotherapy
13%
CD8
13%
Tumor Antigen
11%
CD4
10%
MHC Class I
10%
Antigen Presentation
10%
Soft Tissue
10%
Tumor Necrosis Factor
10%
Monoclonal Antibody
10%
Transcriptomics
10%
Cytotoxic T-Cell
10%
Immune Escape
8%
Immune Response
8%
Beta-2 Microglobulin
7%
